The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | Early detection of amyloidosis, MGUS, and smoldering myeloma: single-center real-world experience
Natalia Schütz, MD, Italian Hospital of Buenos Aires, Buenos Aires, Argentina, discusses work from her center to improve the early detection and diagnosis of amyloidosis, examining factors contributing to diagnostic delays. Dr Schütz also highlighted that patients diagnosed with early monoclonal gammopathy of unknown significance (MGUS) or smoldering myeloma (SMM) often experience anxiety, but earlier diagnosis can aid in better monitoring and outcomes. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
